Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells.

Ernesto Diaz-Flores, PhD, Margaret VanMeter, BS, Jennifer O. Lauchle, M.D., Benjamin S. Braun, M.D.-Ph.D, Kevin M. Shannon, M.D.

Blood (2007) 110 (11): 2196.

https://doi.org/10.1182/blood.V110.11.2196.2196

Published: 2007

Journal Articles

Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition.

Jennifer O. Lauchle, MD, Doan T. Le, MD, Doris Kim, Keiko Akagi, PhD, Matthew F. Gorman, MD, Mary Tran, Judith Sebolt-Leopold, PhD, Linda Wolff, PhD, Luis F. Parada, PhD, Nancy Jenkins, PhD, Neal Copeland, PhD, Kevin M. Shannon, MD

Blood (2007) 110 (11): 594.

https://doi.org/10.1182/blood.V110.11.594.594

Published: 2007

Journal Articles

β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice

Andrew Kim, Kelly Morgan, Diane E. Hasz, Stephen M. Wiesner, Jennifer O. Lauchle, Jennifer L. Geurts, Miechaleen D. Diers, Doan T. Le, Scott C. Kogan, Luis F. Parada, Kevin Shannon, David A. Largaespada

Blood (2006) 109 (4): 1687–1691.

https://doi.org/10.1182/blood-2006-05-025395

Published: 2006

Includes: Supplemental data

Journal Articles

Disease Stage Strongly Modulates Responsiveness to Targeted Agents in Nf1 Mutant Mice with Myeloprolfierative Disease (MPD) and Acute Myeloid Leukemia (AML).

Jennifer O. Lauchle, MD, Doan Le, MD, Doris Kim, BA, Mary Tran, BA, Abigail Peterson, BA, Sally Przybranowski, PhD, Luis Parada, PhD, Linda Wolff, PhD, Judith Leopold, PhD, Kevin M. Shannon, MD

Blood (2005) 106 (11): 496.

https://doi.org/10.1182/blood.V106.11.496.496

Published: 2005

Journal Articles

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

Doan T. Le, Namie Kong, Yuan Zhu, Jennifer O. Lauchle, Abigail Aiyigari, Benjamin S. Braun, Endi Wang, Scott C. Kogan, Michelle M. Le Beau, Luis Parada, Kevin M. Shannon

Blood (2004) 103 (11): 4243–4250.

https://doi.org/10.1182/blood-2003-08-2650

Published: 2004

NARROW

Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells.

Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition.

β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice

Disease Stage Strongly Modulates Responsiveness to Targeted Agents in Nf1 Mutant Mice with Myeloprolfierative Disease (MPD) and Acute Myeloid Leukemia (AML).

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

Email alerts

ASH Publications

American Society of Hematology

Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells.

Mutations That Cooperate with Nf1 Inactivation in Leukemogenesis Influence Therapeutic Response to MEK Inhibition.

β common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice

Disease Stage Strongly Modulates Responsiveness to Targeted Agents in Nf1 Mutant Mice with Myeloprolfierative Disease (MPD) and Acute Myeloid Leukemia (AML).

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only